Affinity Asset Advisors, LLC Argenx Se Transaction History

Affinity Asset Advisors, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$338.91 - $506.01 $2.54 Million - $3.8 Million	7,500 New	7,500 $2.85 Million
Q1 2023 May 15, 2023	BUY	$334.23 - $403.65 $1.92 Million - $2.32 Million	5,750 Added 115.0%	10,750 $4.01 Million
Q4 2022 Feb 13, 2023	BUY	$342.17 - $402.31 $1.71 Million - $2.01 Million	5,000 New	5,000 $1.89 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.